Glucagon/GLP-1 agonists for the treatment of obesity

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9765130
SERIAL NO

14650469

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDIMMUNE LIMITEDMILSTEIN BUILDING GRANTA PARK CAMBRIDGE CB21 6GH UNITED KINGDOM

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Agoram, Balaji Gaithersburg, US 6 3
Antonsson, Madeleine Mölndal, SE 4 3
Bednarek, Maria Cambridge, GB 7 17
Benthem, Lambertus Cambridge, GB 7 3
Burmeister, Nicole Cambridge, GB 4 3
Fairman, David Cambridge, GB 13 20
Fritsch-Fredin, Maria Mölndal, SE 4 3
Jackson, Ronald Cambridge, GB 10 157
Lofmark, Rasmus Jansson Cambridge, GB 4 3
Metcalfe, Jacqueline Cambridge, GB 4 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 19, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 19, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00